Pharma DECODED
Latest edition: 21 May 2024
Share newsletter
Get the full version straight to your inbox.
Exclusive access to our best-in-class data & intelligence
Subscribe now
Spotlight
AstraZeneca to establish $1.5bn ADC production site in Singapore
The design and construction of the site will begin by the end of 2024, to be operational by 2029.
Latest news
FDA grants approval for two Eylea biosimilars for eye conditions
Both hinder vascular endothelial growth factor (VEGF) to prevent abnormal blood vessel growth within the eye.
Final report says UK infected blood scandal “should have been avoided”
Nearly 30,000 people, including children in clinical trials, were infected with hepatitis C and HIV from contaminated blood products in the 1970s and 1980s.
UK clinical trials industry tackles recent changes in the sector
The Annual Outsourcing in Clinical Trials conference will gather pharma experts to discuss the UK clinical trial landscape.
Amgen and AstraZeneca ponder label expansion for Tezspire in COPD
The companies plan to start Phase III trials for Tezspire in COPD despite missing the primary endpoint in the Phase IIb study.
J&J's Tremfya meets endpoints in Phase III ulcerative colitis trial
The company’s monoclonal antibody met primary and secondary endpoints as a maintenance therapy for ulcerative colitis in a Phase III trial.
Faron Pharmaceuticals reports positive data from MDS trial
The combination treatment was found to be well tolerated without demonstrating any dose-limiting toxicity.
Rila Therapeutics doses first cohort in Phase I CKD treatment trial
The study will assess the tolerability, safety, food effect, and pharmacokinetics of RLA-23174.
In our previous edition
Pharma Decoded
Sanders issues warning to Novo Nordisk amid GLP-1 drug price investigation
20 May 2024
Pharma Decoded
Patient access to medicines must be the focus of US drug pricing policy
17 May 2024
Pharma Decoded
KRAS inhibitors: The next frontier beckons
16 May 2024
Still looking?
Search companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Explorer
Access more premium companies when you subscribe to Explorer